<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37666">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616185</url>
  </required_header>
  <id_info>
    <org_study_id>B7791001</org_study_id>
    <secondary_id>PRCA VBIR FIP STUDY</secondary_id>
    <nct_id>NCT02616185</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)</brief_title>
  <official_title>A Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (Vbir) For Prostate Cancer (Pf-06753512)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing
      doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and grade of treatment-emergent adverse events including DLTs</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>DLTs in order to determine the maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response to the selected prostate cancer tumor-antigens</measure>
    <time_frame>Baseline up to Cycle 1 Day 85 and then every 29 and 99 days thereafter up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response specific to the PSMA antigen</measure>
    <time_frame>Baseline up to Cycle 1 Day 85 and then every 29 and 99 days thereafter up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration of tremelimumab (Cmax)</measure>
    <time_frame>Pre-dose on Day 1, Day 29, Day 85 of Cycle 1; pre-dose on Day 29 of Cycle 2 and subsequent cycle up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of tremelimumab (Tmax)</measure>
    <time_frame>Pre-dose on Day 1, Day 29, Day 85 of Cycle 1; pre-dose on Day 29 of Cycle 2 and subsequent cycle up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero extrapolated to infinity of tremelimumab</measure>
    <time_frame>Pre-dose on Day 1, Day 29, Day 85 of Cycle 1; pre-dose on Day 29 of Cycle 2 and subsequent cycle up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations after multiple doses of tremelimumab (Ctrough)</measure>
    <time_frame>Pre-dose on Day 1, Day 29, Day 85 of Cycle 1; pre-dose on Day 29 of Cycle 2 and subsequent cycle up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titers of anti-drug antibodies against tremelimumab</measure>
    <time_frame>From baseline up to Cycle 1 Day 85 and then on Day 1 and Day 29 of each cycle thereafter up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration of sunitinib (Cmax)</measure>
    <time_frame>Day -15, Day -1 at 0 hour, 2, 4 and any time between 6 to 12 hours after sunitinib dosing; Day 1 and Day 29 of Cycle 1; Day 29 of Cycle 2 and subsequent cycles up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of sunitinib (Tmax)</measure>
    <time_frame>Day -15, Day -1 at 0 hour, 2, 4 and any time between 6 to 12 hours after sunitinib dosing; Day 1 and Day 29 of Cycle 1; Day 29 of Cycle 2 and subsequent cycles up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state area under the curve during one dose interval of sunitinib (AUCtau)</measure>
    <time_frame>Day -15, Day -1 at 0 hour, 2, 4 and any time between 6 to 12 hours after sunitinib dosing; Day 1 and Day 29 of Cycle 1; Day 29 of Cycle 2 and subsequent cycles up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titers of neutralizing antibodies against PF-06801591</measure>
    <time_frame>From baseline up to Cycle 1 Day 85 and then on Day 1 and Day 29 of each cycle thereafter up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration of PF-06801591 (Cmax)</measure>
    <time_frame>Pre-dose on Day 1, Day 29, Day 85 of Cycle 1; pre-dose on Day 29 of Cycle 2 and subsequent cycle up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of PF-06801591 (Tmax)</measure>
    <time_frame>Pre-dose on Day 1, Day 29, Day 85 of Cycle 1; pre-dose on Day 29 of Cycle 2 and subsequent cycle up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero extrapolated to infinity of PF-06801591</measure>
    <time_frame>Pre-dose on Day 1, Day 29, Day 85 of Cycle 1; pre-dose on Day 29 of Cycle 2 and subsequent cycle up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations after multiple doses of PF-06801591 (Ctrough)</measure>
    <time_frame>Pre-dose on Day 1, Day 29, Day 85 of Cycle 1; pre-dose on Day 29 of Cycle 2 and subsequent cycle up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06755992</intervention_name>
    <description>PF-06755992 will be administered on Day 1 of each cycle. Two dose levels will be evaluated.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06755990</intervention_name>
    <description>PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TDS-IM Electroporation Device</intervention_name>
    <description>TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>PF-06753388 will be administered every 28 days. Two dose levels will be evaluated.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <other_name>PF-06753388</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Sunitinib will be taken daily. Up to three dose levels may be evaluated to determine the MTD when given in combination with the PrCa VBIR.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06801591</intervention_name>
    <description>PF-06801591 will be administered every 28 days. Two dose levels will be evaluated.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of prostate cancer

          -  Adequate bone marrow, kidney and liver function

          -  Hormone sensitive relapsing prostate cancer after definitive local therapy
             (biochemical relapse) OR

          -  Progressive disease post-surgical castration or during androgen suppression therapy
             (pre-secondary hormone CRPC) OR

          -  Failed prior therapy with a secondary hormone (e.g. enzalutamide, abiraterone) with
             documented progressive disease (post-secondary hormone CRPC)

        Exclusion Criteria:

          -  Cancer-related pain requiring scheduled opioid narcotics for control

          -  ECOG performance status greater than or equal to 2

          -  Concurrent immunotherapy for prostate cancer

          -  History of or active autoimmune disorders or history of inflammatory bowel disorders

          -  Current use of any implanted electronic stimulation device

          -  For biochemically relapsed patients, no concurrent use of ADT or orchiectomy and no
             known prior or current evidence of any metastatic involvement of distant organs

          -  For pre-secondary hormone patients, no prior or concurrent treatment with a secondary
             hormone (e.g. enzalutamide, abiraterone) and no metastasis to organ systems other
             than lymph nodes and/or bone

          -  For post-secondary hormone patients, no concurrent treatment with a secondary hormone
             (e.g. enzalutamide, abiraterone), no metastasis to the liver or brain
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1196</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GU Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center 53rd Street</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center, Sidney Kimmel Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Chemotherapy Services</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University, Sidney Kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC CancerCenter- Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7791001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>November 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
